Translational research in glioblastoma multiforme: Molecular criteria for patient selection

Rafael Rosell, Ramon de las Peñas, Carme Balaña, Mariacarmela Santarpia, Fernanda Salazar, Itziar de Aguirre, Noemi Reguart, Salvador Villa, Jia Wei, Jose Luis Ramirez, Miguel Angel Molina, Santiago Ramon Cajal, David Jablons, Miquel Taron

Research output: Contribution to journalArticlepeer-review


In spite of the dismal outcome of glioblastoma multiforme (GBM), we are in a position to provide a ray of hope to patients and families. Methylation of MGMT in tumor occurs in approximately a third,of patients and predicts meaningful response and survival to adjuvant radiotherapy plus temozolomide. Limited access to tumor tissue in some patients could be circumvented by examining MGMT methylation in circulating serum DNA, although this approach needs to be validated. Molecular signatures are also promising prognostic and predictive markers, and clinical trials should be carried out to validate their use in the selection of patients for specific targeted therapies. Gene expression by quantitative PCR of key components of these molecular signatures could pave the way for easy identification of different subgroups of patients. Translational clinical trials are warranted in order to detect the subgroups of patients resistant to radiotherapy who may derive benefit from novel therapies, including antiangiogenic drugs.

Original languageEnglish
Pages (from-to)219-228
Number of pages10
JournalFuture Oncology
Issue number2
Publication statusPublished - Apr 2008


  • BRCA1
  • GAB1
  • Glioblastoma multiforme
  • MGMT
  • NRP1
  • PTEN

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)


Dive into the research topics of 'Translational research in glioblastoma multiforme: Molecular criteria for patient selection'. Together they form a unique fingerprint.

Cite this